Quantcast

Latest gastroparesis Stories

2009-06-02 08:04:30

Inhaling a dangerous gas could treat a common diabetic condition.

2009-05-05 08:05:00

SAN DIEGO, May 5 /PRNewswire/ -- - Evoke Pharma, Inc., a privately-held specialty pharmaceutical company, announced today that it has initiated a Phase 2b clinical trial to evaluate EVK-001 for the treatment of adults with symptoms of diabetic gastroparesis.

370572c9a414d9bd74461f1845d6423a1
2009-02-27 11:12:08

The US Food and Drug Administration is requiring makers of the heartburn drug Reglan to add a “black box” warning to inform patients that long term or high doses of the drug have been linked to involuntary movement throughout the body.

2008-10-01 06:00:29

Tranzyme Pharma today announced positive Phase IIb results for its first-in-class, highly potent and selective ghrelin agonist, TZP-101, for the management of postoperative ileus (POI).

2008-09-09 03:00:26

AGI Therapeutics Interim financial results for the six months ended 30 June 2008 -- ARDIS-1 now 75% enrolled -- Dublin, Ireland, 9 September 2008 - AGI Therapeutics plc ("AGI" or the"Company") (AIM, IEX: AGI), a speciality pharmaceutical development company focused on gastrointestinal drug products, today reports interim financial results for the six months ended 30 June 2008.

2008-07-22 06:00:17

Tranzyme Pharma, a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal (GI) and metabolic disorders, announced today that the Company has received Notices of Allowance from the U.S.

2008-07-01 09:00:13

Elixir Pharmaceuticals, Inc., today announced the Company has entered an exclusive license agreement with Boston University to key intellectual property covering discoveries regarding the use of modulators of SIRT1, a member of the sirtuin class of protein deacetylase enzymes.

2008-06-23 06:00:06

Tranzyme Pharma announces the successful results from a "Thorough QT/QTc" study of the company's lead product TZP-101, an intravenous gastrointestinal prokinetic agent currently in two Phase IIb trials for the treatment of postoperative ileus (POI) and severe gastroparesis.

2008-06-18 09:00:09

Elixir Pharmaceuticals, Inc., today announced that results from in-vivo preclinical studies with the Company's ghrelin agonist, EX-1314, were presented at the annual meeting of the Endocrine Society. EX-1314 is expected to enter human clinical testing this year.

2008-06-17 06:00:07

Tranzyme Pharma announced today the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development.


Word of the Day
saggar
  • A ceramic container used inside a fuel-fired kiln to protect pots from the flame.
The word 'saggar' may come from 'safeguard'.
Related